Last updated 2 days ago
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
478 patients around the world
Available in Spain, Chile, United States
Regeneron Pharmaceuticals
1Research sites
478Patients around the world
This study is for people with
Non-Hodgkin Lymphoma
Follicular lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Diagnosis of cluster of differentiation 20^+ (CD20^+) FL Grade 1-3a, stage II bulky or stage III / IV.Need for treatment as described in the protocol.Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed tomography (CT) or Magnetic resonance imaging (MRI).Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.Adequate bone marrow function and hepatic function.
- Central nervous system (CNS) lymphoma or leptomeningeal lymphoma.Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma.Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma.Treatment with any systemic anti-lymphoma therapy.Infections and allergy/hypersensitivity to study drug or excipient.
Sites
Inmunocel
Recruiting
StudyOLYMPIA-1
SponsorRegeneron Pharmaceuticals
Conditions
Follicular lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06091254
